Rouen, January 30, 2018 – Robocath, a company that conceives and develops cardiovascular robotic systems for the treatment of vascular diseases, announces today the creation of its medical advisory board including global experts and recognized leaders in interventional cardiology.

This committee will help define the clinical strategy of the company and more broadly contribute to the development of future generations of Robocath’s robotic system products.

Philippe Bencteux, president and founder of Robocath, said: “I’m particularly proud and pleased to welcome these key opinion leaders in interventional cardiology on to our medical advisory board (MAB). We all have a common vision regarding the future of medicine and the key role that robotic systems will play in the treatment of vascular diseases.”

This MAB will include the following experts:

  • Doctor A. Cremonesi, head of the Villa Maria hospital cardiovascular department in Bologna (Italy) for the last 25 years, published many interventional cardiology and peripheral vascular papers. From 2011 to 2013, he was president of the Italian society of interventional cardiology. He has for many years been an active member of the PCR board and received several awards in recognition of his achievements.
  • Professor A. Cribier, professor of medicine and former chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI (Transcatheter Aortic Valve Implantation) procedure, a breakthrough, less invasive interventional treatment for structural heart diseases. Since its creation, the device has been implanted in thousands of patients around the world. He is the author of more than 600 publications and has received several major international medical and scientific awards.
  • Doctor J. Fajadet, co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse, co-director of EuroPCR, one of the most important interventional cardiology congresses in the world. Director of the EAPCI, (European Association of Percutaneous Cardiovascular Interventions) between 2011 and 2014. He is the author of numerous publications and holds several major awards.
  • Professor G. Stone, professor of medicine and director of cardiovascular research and training at the Center for Interventional Therapy at Colombia University Medical Center and at the Cardiovascular Research Foundation, both in New York. Regularly engaged in clinical research and professional education, he has led and published more than 2,000 manuscripts and abstracts and has received several major awards for his work. He is director of the TCT Congress (Transcatheter Cardiovascular Therapeutics), one of the largest interventional cardiology gatherings in the world.


About Robocath

Founded in 2009 by neuroradiologist Philippe Bencteux, Robocath designs and develops innovative robotic solutions to improve the management of the endovascular procedures performed in the treatment of cardiovascular diseases. Of these diseases, heart attack is the leading cause of deaths worldwide.

Thanks to its unique technological know-how, covered by more than 60 international patents, Robocath is contributing to the development of simpler, safer and more intuitive minimally-invasive procedures for the benefit of physicians, patients and healthcare institutions.

Based in Rouen, France, Robocath employs close to 20 staff.